clinical trial · NCT05964335
Cough Reduction in IPF With Nalbuphine ER
Idiopathic Pulmonary FibrosisNAL ERPlaceboNAL ERNAL ER
brief summary
The main purpose of the study is to evaluate the effect of NAL ER on 24-hour cough frequency using objective digital cough monitoring and to assess safety and tolerability of NAL ER.
started
Feb 6, 2024
primary completion
Apr 24, 2025
completion
Apr 24, 2025
last updated
Jun 27, 2025
official title
A Randomized, Double-Blind, Placebo-Controlled, Parallel, 4-Arm Dose Ranging Study of the Safety and Efficacy of Nalbuphine Extended-Release Tablets (NAL ER) for the Treatment of Cough in Idiopathic Pulmonary Fibrosis (IPF)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol